BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free Read more…
During the Healthcare Expo organized that take place in Taïwan between the 30th of November and the 3rd of December, our partner Tokyo Future Style Taiwan had a booth and presented BIOMIMESYS® technology. Dr Dar-Bin Read more…
If you wasn’t there you’ve missed something, a whole lot of stands and propositions of products and ingredients for the cosmetic field ! Océane GUYOT our dermocosmetic chief and Rita HIEN our business developer junior Read more…
One week later after our business trip in Asia, we are lucky to welcome Pr Dar Bin Shieh from National Cheng Kung University (Taiwan) in Lille on the 16th of November. In the morning, we Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined Read more…
🇬🇧 HCS PHARMA will be in Paris for the 15th edition of inescapable COSMET’AGORA event the 10 and 11 january 2023 ! Join Océane GUYOT, project manager in dermocosmetology, and Rita HIEN, business developer junior, Read more…
In order to make known BIOMIMESYS technology, Grégory and Nathalie were in Asia in October during one month. The first step was in Japan. We have worked with our partners from AS ONE and JVC Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into Read more…
We are pleased to welcome Paul Couvreur as a commercial apprentice on board of HCS Pharma. Graduated in international trade and now in an international business Master, Paul decided to get on board of HCS Read more…
We were glad to participate in FIE (Food Ingredients Europe) fair, which took place from the 6th to the 8th of December in Paris (as a new place for the fair France). Elodie attended it Read more…
The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in Read more…
Last week, our project leader Océane GUYOT was in Lisbon to participate in Skin Ageing & Challenges. We had the opportunity to present a short oral entitled Cell Imaging For Dermocosmetic Claims Substantation Through In Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into Read more…
Next week we will have the pleasure to attend FOOD INGREDIENTS EUROPE & HEALTH INGREDIENTS EUROPE (FIE/HIE), which will take place in Paris, Porte de Versailles. Food ingredients Europe has been uniting the world’s leading Read more…
Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a Read more…
BIOMIMESYS® permet de cultiver des cellules en 3D dans des conditions identiques à celle d’un organe humain et en utilisant exclusivement des composés physiologiques. Nous sommes non seulement capables de proposer un environnement dont la composition est celle du tissu désiré, mais qui en plus a les mêmes propriétés mécaniques de rigidité et de porosité.
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human Read more…
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.